Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis

Gong, Wenping; Liang, Yan; Wu, Xueqiong

doi:10.1155/2020/4263079

Cited by 34 publications

(24 citation statements)

References 203 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there are no recommended vaccinal protocols neither established preclinical models to study the efficacy of potential vaccines against the wide variety of NTM. Conversely, animal models for anti-TB vaccine research are well documented, including vertebrates and invertebrates [ 191 ]. As suggested previously [ 192 ], strategies currently being considered for immunization against M. tuberculosis could be exploited against NTM as well.…”

Section: In Vivo Preclinical Models In Vaccine Researchmentioning

confidence: 99%

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

et al. 2020

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) represent an increasingly prevalent etiology of soft tissue infections in animals and humans. NTM are widely distributed in the environment and while, for the most part, they behave as saprophytic organisms, in certain situations, they can be pathogenic, so much so that the incidence of NTM infections has surpassed that of Mycobacterium tuberculosis in developed countries. As a result, a growing body of the literature has focused attention on the critical role that drug susceptibility tests and infection models play in the design of appropriate therapeutic strategies against NTM diseases. This paper is an overview of the in vitro and in vivo models of NTM infection employed in the preclinical phase for early drug discovery and vaccine development. It summarizes alternative methods, not fully explored, for the characterization of anti-mycobacterial compounds.

show abstract

Section: In Vivo Preclinical Models In Vaccine Researchmentioning

confidence: 99%

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Experimental studies to evaluate the vaccine’s efficacy against TB in cattle are expensive and require complex premises to maintain and handle the experimental animals. Testing in goats is less expensive and has been considered as an alternative model for testing prototype vaccines against TB in humans and animals [ 27 , 28 ]. It has been shown that goats develop TB lesions similar to those observed in cattle and humans [ 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Prime Vaccination with Chitosan-Coated Phipps BCG and Boosting with CFP-PLGA against Tuberculosis in a Goat Model

Contreras-Magallanes

Durán-Aguilar

Sosa-Gallegos

et al. 2021

Animals

View full text Add to dashboard Cite

Attempts to improve the immune response and efficacy of vaccines against tuberculosis in cattle, goats, and other animal species have been the focus of research in this field during the last two decades. Improving the vaccine efficacy is essential prior to running long-lasting and expensive field trials. Studies have shown that vaccine protocols utilizing boosting with proteins improve the vaccine efficacy. The use of polymers such as chitosan and PolyLactic-co-Glycolic Acid (PLGA) improves the immune response against different diseases by improving the interaction of antigens with the cellular immune system and modulating the host immune response. This study shows that the prime BCG vaccination, boosted with a culture filtrate protein (CFP), alone or in combination with chitosan and PolyLactic-co-Glycolic Acid (PLGA), have the potential to reduce tuberculosis (TB) dissemination by reducing the number of animals with lesions, the number of lesions per animal, and the size of the lesions in vaccinated animals, compared with those not vaccinated or those vaccinated with BCG alone. The vaccinated groups showed significantly higher Interferon-γ levels in the blood compared to the control, nonvaccinated group after vaccination, after boosting, and after the challenge with the wild-type Mycobacterium bovis strain.

show abstract

“…Mice are by far the most used model in the evaluation of novel TB vaccines, followed by other common mammalian models: guinea pig, rabbit, cattle and non-human primates (NHPs) (reviewed in Gong et al, 2020 ; Myllymäki et al, 2015 ). However, small mammalian models are limited by their lack of natural susceptibility to mycobacterial infection, whereas NHPs raise ethical concerns ( Gong et al, 2020 ; Myllymäki et al, 2015 ). As an alternative to mammalian models, fish models, and especially zebrafish ( Danio rerio ), have gained popularity in TB vaccine development.…”

Section: Introductionmentioning

confidence: 99%

Integrating fish models in tuberculosis vaccine development

Saralahti

Uusi-Mäkelä

Niskanen

et al. 2020

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

Tuberculosis is a chronic infection by Mycobacterium tuberculosis that results in over 1.5 million deaths worldwide each year. Currently, there is only one vaccine against tuberculosis, the Bacillus Calmette–Guérin (BCG) vaccine. Despite widespread vaccination programmes, over 10 million new M. tuberculosis infections are diagnosed yearly, with almost half a million cases caused by antibiotic-resistant strains. Novel vaccination strategies concentrate mainly on replacing BCG or boosting its efficacy and depend on animal models that accurately recapitulate the human disease. However, efforts to produce new vaccines against an M. tuberculosis infection have encountered several challenges, including the complexity of M. tuberculosis pathogenesis and limited knowledge of the protective immune responses. The preclinical evaluation of novel tuberculosis vaccine candidates is also hampered by the lack of an appropriate animal model that could accurately predict the protective effect of vaccines in humans. Here, we review the role of zebrafish (Danio rerio) and other fish models in the development of novel vaccines against tuberculosis and discuss how these models complement the more traditional mammalian models of tuberculosis.

show abstract

Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis

Cited by 34 publications

References 203 publications

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

Prime Vaccination with Chitosan-Coated Phipps BCG and Boosting with CFP-PLGA against Tuberculosis in a Goat Model

Integrating fish models in tuberculosis vaccine development

Contact Info

Product

Resources

About